A recent study suggests that patients who stop using popular GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who stop conventional lifestyle programs.
Findings released in a prominent medical journal shows that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing such treatments need to be cognizant of the risk of fast weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
That rate of recovery suggests a return to starting mass within about 18 months.
Comparing Approaches
The research, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of the injectable medications with conventional dieting.
Scientists point out that people who shed pounds through diet and exercise typically have a slower weight regain—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Regain
Experts suggest the way of the jabs explains the amplified rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 levels several times higher than normal might result in the body to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication results in appetite is uncontrolled, making overeating much more probable."
An Ongoing Issue?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, given the significant potential of weight regain, the treatment is often long-term.
This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the long-term nature of excess weight," similar to managing diseases like high blood pressure.
User Accounts
Users who have discontinued the jabs describe a sudden resurgence of appetite.
"I experienced something that goes on and I was suddenly ravenous," recalled an individual.
The struggle is worsened if individuals have not adopted permanent lifestyle or habit changes during treatment.
Widespread Interest
Survey data suggest that millions of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is more common among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a magic solution and lasting health benefits hinges on combined lifestyle support.
